President and Chief Scientific Officer
320 Logue Avenue
Mountain View, CA. 94043
Phone: 650-254-0786 (Office)
Dr. Zaveri is the Founder, President and Chief Scientific Officer of Astraea Therapeutics, a preclinical discovery company she founded in 2008, whose mission is medication development for under-served diseases of the central nervous system (such as substance abuse and addiction, chronic pain and Parkinson’s disease). A PhD medicinal chemist by training, Dr. Zaveri is a recognized expert in the field of G-protein coupled receptor-targeted- and ion channel-targeted drug discovery for CNS medications. Pioneering discoveries from her laboratory have contributed to the understanding of the pharmacology of drug addiction and pain, and are being advanced into medication development. Dr. Zaveri has been a leader in the discovery and rational design of nociceptin opioid receptor ligands, and compounds developed in her laboratory are under development for substance abuse treatment and chronic pain. Dr. Zaveri’s discovery of the first truly high affinity and selective compounds targeted to the alpha3eta4 nicotinic ion channel receptors garnered tremendous interest in the nicotine addiction research arena and are being developed as smoking cessation medications. Before her entrepreneurial venture at Astraea Therapeutics, Dr. Zaveri was Principal Investigator and Director of the Drug Discovery Program at a nonprofit research institute for over 15 years. Dr. Zaveri has a proven track record of driving drug discovery from ‘target validation to IND’, leading cross-functional teams through to translational development. Dr. Zaveri has been the Chair of the Drug Discovery and Development Interface Section of the American Association of Pharmaceutical Scientists (AAPS) and continues to provide leadership to the AAPS in various committees. She was awarded the AAPS Fellow status in 2014 to recognize the significant impact of her research to the Pharmaceutical Sciences and medication development. Dr. Zaveri also serves on several NIH grant review committees.